Nephrologists Continue to Report High Omontys Awareness, Usage Remains Low


EXTON, Pa.—BioTrends Research Group has released findings from the second wave (W2) of its LaunchTrends: Omontys report. This report surveyed a total of 81 U.S. nephrologists about their current awareness, trial and usage of Affymax/Takeda's Omontys (peginesatide), an erythropoiesis-stimulating agent (ESA) recently approved by the U.S. Food and Drug Administration (FDA) and indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.

The study was fielded approximately three months post-U.S. commercial availability of Omontys. Aided awareness of Omontys has remained about the same as wave 1 (W1) at one-month post-U.S. commercial availability with 78 percent of nephrologists aware of Omontys. The brand name is becoming more known; of those who mention Omontys when asked about new products or news in renal anemia, 85 percent (versus 54 percent in W1) mention the Omontys brand name specifically.

Despite several positives for Omontys (such as high aided physician awareness of the drug, assignment of a HCPCS code, and established contracts with Fresenius and U.S. Renal Care, promotional activity picking-up), the number of nephrologists who have prescribed Omontys remains low in this second wave.

Surveyed nephrologists forecast a significant increase in Omontys patient share in the next six months. For hemodialysis and peritoneal dialysis (PD) patients in particular; Omontys growth is expected at the expense of Amgen's Epogen. In keeping with the approved indication, fewer nephrologists expect to use Omontys in the CKD-non-dialysis (CKD-ND) patient population.

"In this second wave of research, we found a changing dynamic in the way surveyed nephrologists perceive the potential patient types for Omontys. Awareness of the indication has directionally increased, and as such, Omontys is likely to be used as indicated—in the dialysis patient population—anticipated use of the drug in CKD-ND patients has significantly declined since wave 1," said BioTrends' Associate Therapeutic Class Director-Nephrology Rob Dubman. "However, there is a high opportunity for Omontys to increase patient share as evidenced by the fact that surveyed nephrologists believe that over half of their hemodialysis ESA-treated patients are likely Omontys candidates."

comments powered by Disqus